ACRS Stock — Aclaris Therapeutics Inc.: Cash, EV, Pipeline

Share price

$5.50

Market cap

$809.6M

Cash

$91.6M

Enterprise value

$718.0M

Balance sheet

Cash	$91.6M
Debt	$0.0M
Net cash	$91.6M
Enterprise value	$718.0M
Basic shares	139.8M shares
Fully diluted shares	176.3M shares
Fully diluted market cap	$969.6M
Cash per share	$0.66

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ACRS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Oct 24, 2026	ATI-045	Phase 2	Atopic Dermatitis; Atopic; Dermatitis	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Bosakitug

Phase 2 · Active Modality: monoclonal antibody

Aliases ATI-045

Target TSLP

Partnerships Biosion, Inc.: exclusive global license ex-Greater China (Aclaris-licensed); CTTQ licenses Greater China rights from Biosion directly

Indications

Atopic dermatitis (Phase 2)

Catalysts

— second half of 2026

Status note Pipeline disclosure from primary 10-Q Business section. Phase 2 trial in moderate-to-severe AD initiated June 2025. Bosakitug is also studied by CTTQ in China (severe asthma, CRSwNP, COPD); Aclaris clinical focus is dermatological immuno-inflammatory indications.

ATI-2138

Phase 2 · Active Modality: oral small molecule

Target ITK/JAK3

Indications

Atopic dermatitis (Phase 2)

Status note Phase 2a trial in moderate-to-severe AD completed; top-line announced July 2025. Company is exploring additional indications relevant to dual pharmacology, including certain alopecias and other inflammatory disorders.

ATI-052

Phase 1 · Active Modality: bispecific antibody

Target TSLP/IL-4R alpha

Partnerships Biosion, Inc.: exclusive global license ex-Greater China

Indications

Atopic dermatitis (Phase 1)
Asthma (Phase 1)

Catalysts

— second half of 2026
— second half of 2026

Status note Phase 1a SAD/MAD in healthy volunteers completed (Jan 2026); complete top-line from SAD/MAD expected Q2 2026. Phase 1b proof-of-concept trials in AD (initiated Jan 2026) and asthma (initiated Feb 2026).

ATI-9494

Preclinical · Active Modality: oral small molecule

Target ITK/TXK

Catalysts

— second half of 2026

Status note Dual ITK/TXK (Resting Lymphocyte Kinase) inhibitor; other covalent JAK-sparing ITK inhibitors also in discovery/lead optimization.

Lepzacitinib

Stage not disclosed · Active Modality: topical small molecule

Aliases ATI-1777

Target JAK1/JAK3

Partnerships Pediatrix Therapeutics: exclusive Greater China development/commercialization rights (2022); Aclaris seeking global partner (ex-Greater China)

Indications

Atopic dermatitis (Stage not disclosed)

Status note Topical 'soft' JAK 1/3 inhibitor; company is seeking a global development and commercialization partner.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ATI-045
Lead indication	Atopic Dermatitis
Lead phase	Phase 2
Active trials	1
Collaborator trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07011706	Phase 2	Active, not recruiting	Sponsor	ACRS	—	Atopic Dermatitis; Atopic; Dermatitis	—
NCT06374459	Phase 2	Recruiting	Collaborator	Washington University School of Medicine	—	Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer	—
NCT06648434	Phase 1	Recruiting	Collaborator	Washington University School of Medicine	—	Metastatic Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer; Cancer of the Pancreas	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Aclaris Therapeutics, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Frazier Life Sciences	4,925,374	no change	0.57%	2026-08-14
Braidwell LP	2,142,348	+443,232	0.42%	2026-08-14
OrbiMed Advisors	421,500	+421,500	0.04%	2026-08-14
Logos Global Management	200,000	-300,000	0.05%	2026-08-14
ADAR1 Capital Management	0	-132,426	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ACRS — Aclaris Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders